Furthermore, many studies highlight the promise of kinase inhibitors such as larotrectenib in treating NTRK-fusion-positive sarcomas [44] and DNA minor groove-binding agents like trabectedin or mithramycin as potential inhibitors of EWSR1::FLI1-mediated transcription. Here, EWSR1 is linked to sarcoma.